June 30, 2020 / 9:31 PM / 7 days ago

BRIEF-Liminal BioSciences Provides Guidance Update On Certain Expected Key Milestones For 2020

June 30 (Reuters) - Liminal BioSciences Inc:

* LIMINAL BIOSCIENCES PROVIDES GUIDANCE UPDATE ON CERTAIN EXPECTED KEY MILESTONES FOR 2020

* LIMINAL BIOSCIENCES - RE-SUBMISSION OF BLA WITH U.S. FDA FOR RYPLAZIM FOR CONGENITAL PLASMINOGEN DEFICIENCY TREATMENT ANTICIPATED TO BE FILED IN Q3

* LIMINAL BIOSCIENCES - MULTIPLE ASCENDING DOSE PHASE 1 CLINICAL STUDY OF FEZAGEPRAS EXPECTED TO BE INITIATED IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below